Funding
Proximal Ventures raises debut fund to back startups bringing AI to drug development (opens techcrunch.com)
Former SignalFire investor Sahir Raoof's first fund targets AI in pharma.
FundingReported
AI drug development startup Pathos AI closes $237M investment
Context: Bristol Myers Squibb led the Series E at a $3 billion valuation.
From SiliconANGLE: Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers.
Pathos AI · Series E · $237M · with Bristol Myers SquibbAs stated by SiliconANGLE.
- Source
- SiliconANGLE (siliconangle.com)
- Published
- First seen here
- Edition
- Friday, October 23, 2026, ranked 21
- Status
- A publication reported this; the company may not have confirmed it.
- Why it’s here
- Largest disclosed single round in this edition, led by a pharma major.
- Topics
- AI, Health
